MedTrace Logo

Plasma i-FABP as Predictor for Irreversible Bowel Ischemia

NCT01788904 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2013-12-12

No results posted yet for this study

Summary

In the FARAMIS study, we aim to investigate the longitudinal course of intestinal plasma fatty acid binding protein (i-FABP) in patients with acute mesenteric ischemia (AMI) undergoing primary percutaneous angiographic intervention.

The investigators postulate that patients with fully re-established intestinal blood flow and vital intestines will display a significant drop of plasmatic i-FABP within 24 hours, while patients requiring subsequent intestinal resection due to irreversible bowel necrosis will not.

If true, patients requiring laparotomy and bowel resection could be identified and patients in whom angiographic intervention led to successful cure of disease would not be exposed to potentially perilous surgery.

Conditions

  • Acute Mesenteric Ischemia
  • Bowel Necrosis

Sponsors & Collaborators

  • William Cook Europe

    collaborator INDUSTRY

  • University Hospital Regensburg

    lead OTHER

Principal Investigators

  • Peter Heiss, MD, MS · University Hospital Regensburg Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01788904 on ClinicalTrials.gov